Skip to main content

Curative haploidentical BMT in a murine model of X-linked chronic granulomatous disease

International Journal of Hematology volume 102, pages 111–120 (2015)Cite this article

Abstract

Chronic granulomatous disease (CGD) is a primary immunodeficiency disorder characterized by defective microbial killing in phagocytes. Long-term prognosis for CGD patients is generally poor, highlighting the need to develop minimally toxic, curative therapeutic approaches. We here describe the establishment of a mouse model in which X-linked CGD can be cured by allogeneic bone marrow transplantation. Using a combination of non-myeloablative-dose total body irradiation and a single injection of anti-CD40 ligand monoclonal antibody, transplantation of whole bone marrow cells achieved long-lasting mixed chimerism in X-linked CGD mice in a haploidentical transplantation setting. Stable mixed chimerism was maintained for up to 1 year even at a low range (<20 % donor cells), indicating induction of donor-specific tolerance. The regimen induced mild myelosuppression without severe acute complications. Stable chimerism was therapeutic, as it suppressed cutaneous granuloma formation in an in vivo test suited for evaluation of treatment efficacy in murine CGD models. These results warrant future development of a simplified allogeneic hematopoietic cell transplantation regimen that would benefit CGD patients by allowing the use of haploidentical donor grafts without serious concerns of severe treatment-related toxicity.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

References

  1. Winkelstein JA, Marino MC, Johnston RB Jr, Boyle J, Curnutte J, Gallin JI, et al. Chronic granulomatous disease. Report on a national registry of 368 patients. Medicine. 2000;79(3):155–69.

    CAS  PubMed  Article  Google Scholar 

  2. Holland SM. Chronic granulomatous disease. Clin Rev Allergy Immunol. 2010;38(1):3–10.

    CAS  PubMed  Article  Google Scholar 

  3. Seger RA. Advances in the diagnosis and treatment of chronic granulomatous disease. Curr Opin Hematol. 2011;18(1):36–41.

    PubMed  Article  Google Scholar 

  4. Kuijpers T, Lutter R. Inflammation and repeated infections in CGD: two sides of a coin. Cell Mol Life Sci. 2012;69(1):7–15.

    CAS  PubMed Central  PubMed  Article  Google Scholar 

  5. Lindahl JA, Williams FH, Newman SL. Small bowel obstruction in chronic granulomatous disease. J Pediatr Gastroenterol Nutr. 1984;3(4):637–40.

    CAS  PubMed  Article  Google Scholar 

  6. Morgenstern DE, Gifford MA, Li LL, Doerschuk CM, Dinauer MC. Absence of respiratory burst in X-linked chronic granulomatous disease mice leads to abnormalities in both host defense and inflammatory response to Aspergillus fumigatus. J Exp Med. 1997;185(2):207–18.

    CAS  PubMed Central  PubMed  Article  Google Scholar 

  7. Ahlin A, Fugelang J, de Boer M, Ringden O, Fasth A, Winiarski J. Chronic granulomatous disease-haematopoietic stem cell transplantation versus conventional treatment. Acta Paediatr. 2013;102(11):1087–94.

    PubMed  Google Scholar 

  8. Kang EM, Marciano BE, DeRavin S, Zarember KA, Holland SM, Malech HL. Chronic granulomatous disease: overview and hematopoietic stem cell transplantation. J Allergy Clin Immunol. 2011;127(6):1319–26 (quiz 27–28).

    PubMed Central  PubMed  Article  Google Scholar 

  9. Maeda Y. Pathogenesis of graft-versus-host disease: innate immunity amplifying acute alloimmune responses. Int J Hematol. 2013;98(3):293–9.

    CAS  PubMed  Article  Google Scholar 

  10. Paczesny S, Raiker N, Brooks S, Mumaw C. Graft-versus-host disease biomarkers: omics and personalized medicine. Int J Hematol. 2013;98(3):275–92.

    CAS  PubMed Central  PubMed  Article  Google Scholar 

  11. Kikuta A, Ito M, Mochizuki K, Akaihata M, Nemoto K, Sano H, et al. Nonmyeloablative stem cell transplantation for nonmalignant diseases in children with severe organ dysfunction. Bone Marrow Transplant. 2006;38(10):665–9.

    CAS  PubMed  Article  Google Scholar 

  12. Gozdzik J, Pituch-Noworolska A, Skoczen S, Czogala W, Wedrychowicz A, Baran J, et al. Allogeneic haematopoietic stem cell transplantation as therapy for chronic granulomatous disease—single centre experience. J Clin Immunol. 2011;31(3):332–7.

    PubMed Central  PubMed  Article  Google Scholar 

  13. Gungor T, Halter J, Klink A, Junge S, Stumpe KD, Seger R, et al. Successful low toxicity hematopoietic stem cell transplantation for high-risk adult chronic granulomatous disease patients. Transplantation. 2005;79(11):1596–606.

    PubMed  Article  Google Scholar 

  14. Horwitz ME, Barrett AJ, Brown MR, Carter CS, Childs R, Gallin JI, et al. Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell-depleted hematopoietic allograft. N Engl J Med. 2001;344(12):881–8.

    CAS  PubMed  Article  Google Scholar 

  15. Hasegawa D, Fukushima M, Hosokawa Y, Takeda H, Kawasaki K, Mizukami T, et al. Successful treatment of chronic granulomatous disease with fludarabine-based reduced-intensity conditioning and unrelated bone marrow transplantation. Int J Hematol. 2008;87(1):88–90.

    CAS  PubMed  Article  Google Scholar 

  16. Takeuchi Y, Ito H, Kurtz J, Wekerle T, Ho L, Sykes M. Earlier low-dose TBI or DST overcomes CD8+ T-cell-mediated alloresistance to allogeneic marrow in recipients of anti-CD40L. Am J Transplant. 2004;4(1):31–40.

    CAS  PubMed  Article  Google Scholar 

  17. Pollock JD, Williams DA, Gifford MA, Li LL, Du X, Fisherman J, et al. Mouse model of X-linked chronic granulomatous disease, an inherited defect in phagocyte superoxide production. Nat Genet. 1995;9(2):202–9.

    CAS  PubMed  Article  Google Scholar 

  18. Setsukinai K, Urano Y, Kakinuma K, Majima HJ, Nagano T. Development of novel fluorescence probes that can reliably detect reactive oxygen species and distinguish specific species. J Biol Chem. 2003;278(5):3170–5.

    CAS  PubMed  Article  Google Scholar 

  19. Tomita Y, Sachs DH, Khan A, Sykes M. Additional monoclonal antibody (mAB) injections can replace thymic irradiation to allow induction of mixed chimerism and tolerance in mice receiving bone marrow transplantation after conditioning with anti-T cell mABs and 3-Gy whole body irradiation. Transplantation. 1996;61(3):469–77.

    CAS  PubMed  Article  Google Scholar 

  20. Petersen JE, Hiran TS, Goebel WS, Johnson C, Murphy RC, Azmi FH, et al. Enhanced cutaneous inflammatory reactions to Aspergillus fumigatus in a murine model of chronic granulomatous disease. J Invest Dermatol. 2002;118(3):424–9.

    CAS  PubMed  Article  Google Scholar 

  21. Durham MM, Bingaman AW, Adams AB, Ha J, Waitze SY, Pearson TC, et al. Cutting edge: administration of anti-CD40 ligand and donor bone marrow leads to hemopoietic chimerism and donor-specific tolerance without cytoreductive conditioning. J Immunol. 2000;165(1):1–4.

    CAS  PubMed  Article  Google Scholar 

  22. Wekerle T, Kurtz J, Ito H, Ronquillo JV, Dong V, Zhao G, et al. Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment. Nat Med. 2000;6(4):464–9.

    CAS  PubMed  Article  Google Scholar 

  23. Nikolic B, Takeuchi Y, Leykin I, Fudaba Y, Smith RN, Sykes M. Mixed hematopoietic chimerism allows cure of autoimmune diabetes through allogeneic tolerance and reversal of autoimmunity. Diabetes. 2004;53(2):376–83.

    CAS  PubMed  Article  Google Scholar 

  24. Takeuchi E, Shinohara N, Takeuchi Y. Cognate interaction plays a key role in the surveillance of autoreactive B cells in induced mixed bone marrow chimerism in BXSB lupus mice. Autoimmunity. 2011;44(5):363–72.

    CAS  PubMed  Article  Google Scholar 

  25. Grez M, Reichenbach J, Schwable J, Seger R, Dinauer MC, Thrasher AJ. Gene therapy of chronic granulomatous disease: the engraftment dilemma. Mol Ther. 2011;19(1):28–35.

    CAS  PubMed Central  PubMed  Article  Google Scholar 

  26. Hoenig M, Niehues T, Siepermann K, Jacobsen EM, Schutz C, Furlan I, et al. Successful HLA haploidentical hematopoietic SCT in chronic granulomatous disease. Bone Marrow Transplant. 2014;49(10):1337–8.

    CAS  PubMed  Article  Google Scholar 

  27. Seger RA, Gungor T, Belohradsky BH, Blanche S, Bordigoni P, Di Bartolomeo P, et al. Treatment of chronic granulomatous disease with myeloablative conditioning and an unmodified hemopoietic allograft: a survey of the European experience, 1985–2000. Blood. 2002;100(13):4344–50.

    CAS  PubMed  Article  Google Scholar 

  28. Martinez CA, Shah S, Shearer WT, Rosenblatt HM, Paul ME, Chinen J, et al. Excellent survival after sibling or unrelated donor stem cell transplantation for chronic granulomatous disease. J Allergy Clin Immunol. 2012;129(1):176–83.

    PubMed  Article  Google Scholar 

  29. Soncini E, Slatter MA, Jones LB, Hughes S, Hodges S, Flood TJ, et al. Unrelated donor and HLA-identical sibling haematopoietic stem cell transplantation cure chronic granulomatous disease with good long-term outcome and growth. Br J Haematol. 2009;145(1):73–83.

    CAS  PubMed  Article  Google Scholar 

  30. Schuetz C, Hoenig M, Schulz A, Lee-Kirsch MA, Roesler J, Friedrich W, et al. Successful unrelated bone marrow transplantation in a child with chronic granulomatous disease complicated by pulmonary and cerebral granuloma formation. Eur J Pediatr. 2007;166(8):785–8.

    PubMed  Article  Google Scholar 

  31. Dinauer MC, Gifford MA, Pech N, Li LL, Emshwiller P. Variable correction of host defense following gene transfer and bone marrow transplantation in murine X-linked chronic granulomatous disease. Blood. 2001;97(12):3738–45.

    CAS  PubMed  Article  Google Scholar 

  32. Sykes M. Mixed chimerism and transplant tolerance. Immunity. 2001;14(4):417–24.

    CAS  PubMed  Article  Google Scholar 

  33. Fehr T, Takeuchi Y, Kurtz J, Wekerle T, Sykes M. Early regulation of CD8 T cell alloreactivity by CD4+ CD25- T cells in recipients of anti-CD154 antibody and allogeneic BMT is followed by rapid peripheral deletion of donor-reactive CD8+ T cells, precluding a role for sustained regulation. Eur J Immunol. 2005;35(9):2679–90.

    CAS  PubMed  Article  Google Scholar 

  34. Kurtz J, Shaffer J, Lie A, Anosova N, Benichou G, Sykes M. Mechanisms of early peripheral CD4 T-cell tolerance induction by anti-CD154 monoclonal antibody and allogeneic bone marrow transplantation: evidence for anergy and deletion but not regulatory cells. Blood. 2004;103(11):4336–43.

    CAS  PubMed  Article  Google Scholar 

  35. Wekerle T, Sayegh MH, Hill J, Zhao Y, Chandraker A, Swenson KG, et al. Extrathymic T cell deletion and allogeneic stem cell engraftment induced with costimulatory blockade is followed by central T cell tolerance. J Exp Med. 1998;187(12):2037–44.

    CAS  PubMed Central  PubMed  Article  Google Scholar 

  36. Elgueta R, Benson MJ, de Vries VC, Wasiuk A, Guo Y, Noelle RJ. Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev. 2009;229(1):152–72.

    CAS  PubMed  Article  Google Scholar 

  37. Boumpas DT, Furie R, Manzi S, Illei GG, Wallace DJ, Balow JE, et al. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum. 2003;48(3):719–27.

    CAS  PubMed  Article  Google Scholar 

  38. Patel VL, Schwartz J, Bussel JB. The effect of anti-CD40 ligand in immune thrombocytopenic purpura. Br J Haematol. 2008;141(4):545–8.

    CAS  PubMed  Article  Google Scholar 

  39. Kawai T, Andrews D, Colvin RB, Sachs DH, Cosimi AB. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat Med. 2000;6(2):114.

    CAS  Article  Google Scholar 

  40. Robles-Carrillo L, Meyer T, Hatfield M, Desai H, Davila M, Langer F, et al. Anti-CD40L immune complexes potently activate platelets in vitro and cause thrombosis in FCGR2A transgenic mice. J Immunol. 2010;185(3):1577–83.

    CAS  PubMed  Article  Google Scholar 

  41. Xie JH, Yamniuk AP, Borowski V, Kuhn R, Susulic V, Rex-Rabe S, et al. Engineering of a novel anti-CD40L domain antibody for treatment of autoimmune diseases. J Immunol. 2014;192(9):4083–92.

    CAS  PubMed  Article  Google Scholar 

Download references

Acknowledgments

We thank Dr. A. S. Knisely for critical reading of the manuscript, Dr. Michiko Abe for the Aspergillus fumigatus debris suspension, Dr. Yasuteru Urano for fluorescent probes and his technical advice, Dr. Yasunori Ota for histopathological analysis, and Dr. Masanori Nojima for statistical analysis. This work was supported in part of by a JSPS KAKENHI Grant-in-Aid for Yasuo Takeuchi and Makoto Otsu, and by grants from the Ministry of Health, Labor and Welfare and National Center for Child Health and Development (M. Onodera).

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Affiliations

  1. Division of Nephrology, Department of Internal Medicine, Kitasato University School of Medicine, Sagamihara, Japan

    Yasuo Takeuchi

  2. Department of Immunology, Kitasato University School of Medicine, Sagamihara, Japan

    Yasuo Takeuchi & Emiko Takeuchi

  3. Department of Hematology, Kitasato University School of Medicine, Sagamihara, Japan

    Takashi Ishida

  4. Department of Human Genetics, National Center for Child Health and Development, Tokyo, Japan

    Masafumi Onodera

  5. Division of Stem Cell Therapy, Center for Stem Cell Biology and Regenerative Medicine, Institute of Medical Science, University of Tokyo, Tokyo, Japan

    Takashi Ishida, Hiromitsu Nakauchi & Makoto Otsu

  6. Stem Cell Bank and Division of Stem Cell Processing, Center for Stem Cell Biology and Regenerative Medicine, Institute of Medical Science, University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan

    Makoto Otsu

Authors
  1. Yasuo Takeuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Emiko Takeuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Takashi Ishida
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Masafumi Onodera
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hiromitsu Nakauchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Makoto Otsu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Makoto Otsu.

Additional information

This work was performed in the Center for Stem Cell Biology and Regenerative Medicine, Institute of Medical Science, University of Tokyo.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (MOV 1939 kb)

Supplementary material 2 (MOV 1469 kb)

Supplementary material 3 (DOC 54 kb)

Supplementary material 4 (TIFF 3 kb)

Supplementary material 5 (TIFF 8 kb)

Supplementary material 6 (TIFF 28327 kb)

Supplementary material 7 (TIFF 222 kb)

About this article

Verify currency and authenticity via CrossMark

Cite this article

Takeuchi, Y., Takeuchi, E., Ishida, T. et al. Curative haploidentical BMT in a murine model of X-linked chronic granulomatous disease. Int J Hematol 102, 111–120 (2015). https://doi.org/10.1007/s12185-015-1799-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-015-1799-8

Keywords

  • Chronic granulomatous disease
  • Haploidentical hematopoietic cell transplantation
  • Non-myeloablative conditioning
  • Anti-CD40 ligand therapy
  • Tolerance